ADC Collaboration Opportunities Peak Bio is pursuing Trop2 PH1 antibody-drug conjugate development and is open to external collaborations for clinical development and potential commercialization of this asset and other novel payloads.

Strategic Growth Signals A recent board appointment indicates a strategic growth trajectory, making Peak Bio a suitable partner for co development, licensing, or equity-backed collaborations with biotech or pharma players seeking to expand oncology and rare disease pipelines.

Formal Vendor Pathways Peak Bio restricts recruiter contact and requires a formal HR approved vendor agreement to engage; plan outreach through official channels and present a compelling, compliant value proposition.

Ecosystem Proximity Located in Palo Alto, Peak Bio can leverage nearby academic institutions, venture networks, and CROs/CMOs to accelerate preclinical and clinical work and facilitate rapid scientific collaboration.

Financing & Deal Structure With a mid sized revenue profile and a focused pipeline, Peak Bio may favor structured deals with milestones and shared risk, making them a fit for partnerships that align development milestones with funding resources.